TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8198909

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 99

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 99

Group type: COMPARATOR
Intervention: All groups (Halothane, Enflurane, Isoflurane, Propofol)
Number of subjects: 99
Study: 3116071

Group type: EXPERIMENTAL
Intervention: terbutaline sulfate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: nitroglycerin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: aminophylline
Number of subjects: 15

Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 15
Study: 31060529

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 48
Study: 28333093

Group type: EXPERIMENTAL
Intervention: 80 g/day dry-cured pork ham
Number of subjects: 38

Group type: COMPARATOR
Intervention: 100 g/day cooked ham (control product)
Number of subjects: 38
Study: 25049068

Group type: EXPERIMENTAL
Intervention: De novo enteric-coated mycophenolate sodium (MPS)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Delayed-onset everolimus (RAD)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: MPS
Number of subjects: 164

Group type: COMPARATOR
Intervention: RAD
Number of subjects: 164
Study: 24130005

Group type: EXPERIMENTAL
Intervention: Exercise + Alagebrium (200 mg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sedentary + Alagebrium (200 mg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Exercise + Placebo
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sedentary + Placebo
Number of subjects: 62
Study: 20814338

Group type: EXPERIMENTAL
Intervention: Brief parenting discussion group (2-hour session with follow-up calls)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 67
Study: 19938212

Group type: EXPERIMENTAL
Intervention: Real intradermal acupuncture (RA group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sham acupuncture (SA group)
Number of subjects: 52
Study: 17040007

Group type: EXPERIMENTAL
Intervention: Nocturnal overdrive pacing (NOP) at 75 bpm
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control at 45 bpm
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nocturnal overdrive pacing (NOP)
Number of subjects: 19
Study: 15457450

Group type: COMPARATOR
Intervention: 18-30 year old group
Number of subjects: 30

Group type: COMPARATOR
Intervention: 66-86 year old group
Number of subjects: 30
Study: 10994920

Group type: EXPERIMENTAL
Intervention: Modified Back-Saver Sit-and-Reach (MBS) test
Number of subjects: 158

Group type: COMPARATOR
Intervention: Classical Sit-and-Reach (CSR) test
Number of subjects: 158

Group type: COMPARATOR
Intervention: Back-Saver Sit-and-Reach (BS) test
Number of subjects: 158

Group type: COMPARATOR
Intervention: V Sit-and-Reach (VSR) test
Number of subjects: 158
Study: 9478258

Group type: EXPERIMENTAL
Intervention: Classification of patients based on origin of coma, duration of stay, future evolution, and cost of treatment.
Number of subjects: 515
Study: 8419869

Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash (5% solution)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo solution (control group)
Number of subjects: 30
Study: 31329402

Group type: EXPERIMENTAL
Intervention: ETCS
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: ETCS + AHA-Ret
Number of subjects: 52
Study: 28569449

Group type: EXPERIMENTAL
Intervention: Selective enamel etching
Number of subjects: 75

Group type: COMPARATOR
Intervention: Self-etching approach
Number of subjects: 75
Study: 25709685

Group type: EXPERIMENTAL
Intervention: Individualized dialysate sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stepwise sodium profile
Number of subjects: 0
Study: 23158477

Group type: COMPARATOR
Intervention: Alternative sequence (ALT)
Number of subjects: 22

Group type: COMPARATOR
Intervention: ERC 2005 and ERC 2010 guidelines
Number of subjects: 22
Study: 19551502

Group type: EXPERIMENTAL
Intervention: Peer support services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community mental health services (Control)
Number of subjects: 0
Study: 18303382

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%
Number of subjects: 48
Study: 16527792

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 14563605

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) using an estro-progestin association (estradiol + a progestin compound), given continuously or with a 5-day interruption each month, mean duration of treatment 2.5 years.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Control group (patients without HRT)
Number of subjects: 230
Study: 10715359

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 8956394

Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac added to the lidocaine used for IVRA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 mg ketorolac added to the lidocaine used for wound infiltration
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no additional medications)
Number of subjects: 60
Study: 1347237

Group type: EXPERIMENTAL
Intervention: MgSO4 (30 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3896019

Group type: EXPERIMENTAL
Intervention: Lateral cutaneous nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: No block (Control)
Number of subjects: 0
Study: 31429601

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy‐Adolescent Skills Training (IPT‐AST)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Group Counseling (GC)
Number of subjects: 186
Study: 29934667

Group type: EXPERIMENTAL
Intervention: Tolvaptan (TLV) ≤ 15 mg/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Furosemide (FUR) ≤ 40 mg/day
Number of subjects: 81
Study: 27824375

Group type: EXPERIMENTAL
Intervention: Wavefront-guided ablation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Topography-guided ablation
Number of subjects: 68
Study: 25064436

Group type: EXPERIMENTAL
Intervention: RFA and percutaneous iodine‐125 seed implantation (RFA‐(125)I)
Number of subjects: 136

Group type: COMPARATOR
Intervention: RFA‐only
Number of subjects: 136
Study: 22508022

Group type: EXPERIMENTAL
Intervention: Wii Fit group (n=11)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Matter of Balance Group (n=11)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 32
Study: 19643946

Group type: EXPERIMENTAL
Intervention: 6-month conditioning programme (3 hours of sports per week)
Number of subjects: 38
Study: 17039794

Group type: EXPERIMENTAL
Intervention: Batroxobin (0.5 ml, 2 BU/ml)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Dexamethasone (2 mg/ml)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Batroxobin and Dexamethasone
Number of subjects: 156
Study: 14702587

Group type: EXPERIMENTAL
Intervention: Weight management intervention (two weight management programs and usual care)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Recruitment strategies (partnering with community health centers, positive reinforcement, social supportiveness, monitoring progress, free transportation)
Number of subjects: 189
Study: 11641593

Group type: EXPERIMENTAL
Intervention: Lubeluzole (7.5 mg i.v. over 1 h, then continuous 5‐day infusion of 10 mg/day)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 9207368

Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (10^7 or 10^9 cfu) in inpatient volunteers
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (10^8 or 10^9 cfu) in outpatient volunteers
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo in outpatient volunteers
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (all doses)
Number of subjects: 62
Study: 8110249

Group type: EXPERIMENTAL
Intervention: 16-hour transdermal nicotine patch
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 220
Study: 3625405

Group type: EXPERIMENTAL
Intervention: Steel cannulas
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Intravenous medication administration
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition solutions
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Increasing cannula gauge
Number of subjects: 151

Group type: COMPARATOR
Intervention: Gravity-controlled infusion device delivery
Number of subjects: 151

Group type: COMPARATOR
Intervention: Potassium concentrations less than or equal to 20 mEq/L
Number of subjects: 151
Study: 30367723

Group type: COMPARATOR
Intervention: Autogenous bone plus deproteinized bovine bone mineral (DBBM) with collagen membrane (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft (FDBA) with collagen membrane (Test)
Number of subjects: 48
Study: 28670823

Group type: EXPERIMENTAL
Intervention: HPV/cytology cotesting (intervention group)
Number of subjects: 773

Group type: COMPARATOR
Intervention: Cytology-only (control group)
Number of subjects: 773
Study: 27434314

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M) injectable
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral paliperidone extended-release (ER)
Number of subjects: 0
Study: 25059094

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 80
Study: 21890583

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg males; 0.63 g/kg females)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Soft drink
Number of subjects: 90

Group type: COMPARATOR
Intervention: Threat before Drink, Threat after Drink, No-Threat Control
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alcohol problems severity
Number of subjects: 90
Study: 19216597

Group type: EXPERIMENTAL
Intervention: Highly filled (58%) resin sealants applied to incisors and canines
Number of subjects: 60

Group type: COMPARATOR
Intervention: No sealant (control group) applied to contralateral teeth
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DIAGNOdent measurements for sealed teeth
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DIAGNOdent measurements excluding 28 teeth with visible lesions
Number of subjects: 60
Study: 17290029

Group type: EXPERIMENTAL
Intervention: Pioglitazone (titrated to 45 mg)
Number of subjects: 5238
Study: 16084051

Group type: EXPERIMENTAL
Intervention: Conventional surgery combined with 5‐fluorouracil and leucovorin, or irinotecan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional surgery and systemic chemotherapy
Number of subjects: 50
Study: 12370501

Group type: EXPERIMENTAL
Intervention: Interleukin-2 (4.5 x 10(6) IU subcutaneously twice daily for 5 days every 6 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (HAART alone)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 72
Study: 10507377

Group type: EXPERIMENTAL
Intervention: SSEP with bilaterally normal CCT
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: SSEP with any delay in CCT
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: SSEP with unilateral absence of cortical component
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: SSEP with bilateral absence of cortical component
Number of subjects: 105
Study: 8567827

Group type: EXPERIMENTAL
Intervention: Single dose of 5 mg mifepristone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Multiple dose of 5 mg/day for 3 days (starting when leading follicle was 14-16 mm)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Multiple dose of 5 mg/day for 3 days (starting when leading follicle was 6-11 mm)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2257796

Group type: EXPERIMENTAL
Intervention: Paracetamol (1000 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid (1000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6159957

Group type: EXPERIMENTAL
Intervention: BCG and 5‐fluorouracil
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil
Number of subjects: 78

Group type: COMPARATOR
Intervention: No additional treatment after palliative resection
Number of subjects: 78
Study: 30810703

Group type: EXPERIMENTAL
Intervention: Lotus valve
Number of subjects: 912

Group type: COMPARATOR
Intervention: CoreValve
Number of subjects: 912
Study: 28321826

Group type: EXPERIMENTAL
Intervention: Probiotics (Kidilact® sachet containing Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Bifidobacterium infantis, Bifidobacterium breve, and Streptococcus thermophiles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo sachets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics (Kidilact® sachet)
Number of subjects: 0
Study: 25809828

Group type: EXPERIMENTAL
Intervention: VSL#3 treatment
Number of subjects: 31
Study: 23328275

Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg QD for 5 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Empagliflozin 50 mg QD and Linagliptin 5 mg QD for 7 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Linagliptin 5 mg QD for 7 days
Number of subjects: 16
Study: 22333547

Group type: EXPERIMENTAL
Intervention: Aspiration-positive group (n = 38)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Aspiration-negative group (n = 28)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (n = 66)
Number of subjects: 132
Study: 19448187

Group type: EXPERIMENTAL
Intervention: 50 hours of computerized auditory training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control condition using computer games
Number of subjects: 55
Study: 17277011

Group type: EXPERIMENTAL
Intervention: Intensive district-level training workshops and supportive supervision visits
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cascade training package
Number of subjects: 72
Study: 15474134

Group type: EXPERIMENTAL
Intervention: Corticosteroids (methylprednisolone)
Number of subjects: 10008

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10008
Study: 11840382

Group type: COMPARATOR
Intervention: Normotensive pregnancy (group 2)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Preeclampsia (group 3)
Number of subjects: 85
Study: 9541433

Group type: EXPERIMENTAL
Intervention: betaxolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: levobunolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 12
Study: 8021064

Group type: EXPERIMENTAL
Intervention: RM cup
Number of subjects: 120

Group type: COMPARATOR
Intervention: PCA cup
Number of subjects: 120
Study: 2704497

Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (24 mg of betamethasone)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ampicillin (2 g intravenous every 6 hours)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Both corticosteroids and ampicillin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Neither ampicillin nor corticosteroids (Control Group I)
Number of subjects: 165
Study: 894647

Group type: EXPERIMENTAL
Intervention: Monistat cream (miconazole nitrate 2%) for 7 days
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Monistat cream (miconazole nitrate 2%) for 10 days
Number of subjects: 139

Group type: COMPARATOR
Intervention: Monistat cream (miconazole nitrate 2%) for 14 days
Number of subjects: 139
Study: 31533676

Group type: EXPERIMENTAL
Intervention: 12-session family-and group-based cognitive-behavioral intervention to prevent youth depression
Number of subjects: 40
Study: 26187939

Group type: EXPERIMENTAL
Intervention: Fast-track protocol (24 hours to 12 hours in 1 day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard protocol (2 days to transition)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fast-track protocol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 63
Study: 1426215

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 micrograms b.i.d.
Number of subjects: 667

Group type: COMPARATOR
Intervention: Salbutamol, 200 micrograms q.i.d.
Number of subjects: 667
Study: 22902198

Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo (GEXP)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment (baseline period)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment (6-month follow-up)
Number of subjects: 8
Study: 20416236

Group type: EXPERIMENTAL
Intervention: Primary care with parallel father testing (n=677)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Primary care with sequential father testing (n=590)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Standard care (n=441)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Standard care (n=90)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Primary care with parallel testing
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Primary care with sequential testing
Number of subjects: 1441
Study: 18983791

Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (20 g/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15659079

Group type: EXPERIMENTAL
Intervention: Glibenclamide (5 mg, b.i.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Gliclazide (80 mg, b.i.d.)
Number of subjects: 15
Study: 12641684

Group type: EXPERIMENTAL
Intervention: Halothane 4% in 2:1 ratio of air:O2 mixture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in 2:1 ratio of air:O2 mixture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control ECG recording before induction of anaesthesia
Number of subjects: 50
Study: 10321537

Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.3 mg atropine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ocular administration of 0.3 mg atropine
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous and ocular administration of 0.3 mg atropine
Number of subjects: 6
Study: 8889087

Group type: EXPERIMENTAL
Intervention: Rivermead Behavioural Memory Test
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EMQ20 questionnaire
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Memory aids usage
Number of subjects: 70
Study: 1753598

Group type: EXPERIMENTAL
Intervention: ISDN + captopril
Number of subjects: 14

Group type: COMPARATOR
Intervention: ISDN
Number of subjects: 14

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14
Study: 6347689

Group type: EXPERIMENTAL
Intervention: Ioxaglate (low-osmolar contrast media)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diatrizoate (high-osmolar contrast media)
Number of subjects: 47
Study: 30946150

Group type: EXPERIMENTAL
Intervention: 3 days a week (3W) Atripla
Number of subjects: 61

Group type: COMPARATOR
Intervention: Once-daily Atripla
Number of subjects: 61
Study: 29855315

Group type: EXPERIMENTAL
Intervention: Bundled payment program offering $5000 for the first year of localized breast cancer treatment
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Bundled payment program offering $15,000 for the first year of localized breast cancer treatment
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Bundled payment program offering $20,000 for the first year of localized breast cancer treatment
Number of subjects: 460
Study: 26858335

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (EPO) 40,000 IU subcutaneously once a week
Number of subjects: 2098

Group type: COMPARATOR
Intervention: Best standard of care
Number of subjects: 2098
Study: 23907785

Group type: EXPERIMENTAL
Intervention: Acoustic Coordinated Reset (CR) neuromodulation therapy, delivered 4-6 hours/day for more than 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acoustic Coordinated Reset (CR) neuromodulation therapy
Number of subjects: 0
Study: 21542113

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) using paclitaxel-eluting stents
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1800
Study: 19448233

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular brachial plexus block
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nerve stimulation infraclavicular brachial plexus block
Number of subjects: 50
Study: 17148942

Group type: EXPERIMENTAL
Intervention: Liposomal dispersion with PVP‐I (2.2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposomal dispersion with PVP‐I (4.4%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Liposomal dispersion with PVP‐I (0%)
Number of subjects: 0
Study: 16943223

Group type: EXPERIMENTAL
Intervention: hrHPV testing added to cervical screening
Number of subjects: 0
Study: 15181065

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 7
Study: 10808574

Group type: EXPERIMENTAL
Intervention: Grippol trivalent polymer-subunit influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8606276

Group type: EXPERIMENTAL
Intervention: Hydralazine/isosorbide dinitrate
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 390

Group type: COMPARATOR
Intervention: Prazosin and placebo therapy
Number of subjects: 390
Study: 1484191

Group type: EXPERIMENTAL
Intervention: Controlled-release morphine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate-release morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 3912314

Group type: EXPERIMENTAL
Intervention: Pirenzepine, 50 mg three times a day for 6 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Carbenoxolone, 100 mg three times a day for one week followed by 50 mg three times a day for the remaining five weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Carbenoxolone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 66